QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
NASDAQ:PBYI

Puma Biotechnology - PBYI Stock Forecast, Price & News

$4.62
-0.14 (-2.94%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.62
$4.81
50-Day Range
$3.98
$5.08
52-Week Range
$1.60
$5.16
Volume
264,222 shs
Average Volume
327,397 shs
Market Capitalization
$210.86 million
P/E Ratio
21.00
Dividend Yield
N/A
Price Target
$8.00

Puma Biotechnology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
73.2% Upside
$8.00 Price Target
Short Interest
Healthy
2.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$172,216 Sold Last Quarter
Proj. Earnings Growth
-57.89%
From $0.19 to $0.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

206th out of 1,026 stocks

Pharmaceutical Preparations Industry

90th out of 504 stocks

PBYI stock logo

About Puma Biotechnology (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Stock News Headlines

Free ebook: 3 Rules to Picking the Right Stocks
Learn the 6 greatest stock market myths – 3 rules to pick the right stocks – Powerful techniques to accurately value stocks – Insights on stock valuation and stock market cycles – Secrets revealed on how to successfully manage your portfolio and much more… pixel
PBYI.OQ - | Stock Price & Latest News | Reuters
Puma Biotechnology, Inc. (PBYI)
Why Shares of Puma Biotechnology Rose This Week
Free ebook: 3 Rules to Picking the Right Stocks
Learn the 6 greatest stock market myths – 3 rules to pick the right stocks – Powerful techniques to accurately value stocks – Insights on stock valuation and stock market cycles – Secrets revealed on how to successfully manage your portfolio and much more… pixel
15 Best Affordable Stocks Under $30
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
Short Volatility Alert: Puma Biotechnology, Inc.
H.C. Wainwright Keeps Their Buy Rating on Puma Biotechnology (PBYI)
Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Profit Outlook
See More Headlines
Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Company Calendar

Last Earnings
11/04/2021
Today
2/08/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PBYI
Employees
196
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+73.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-29,130,000.00
Pretax Margin
4.64%

Debt

Sales & Book Value

Annual Sales
$253.20 million
Book Value
($0.06) per share

Miscellaneous

Free Float
35,964,000
Market Cap
$210.86 million
Optionable
Optionable
Beta
1.01

Key Executives

  • Alan H. AuerbachAlan H. Auerbach
    Chairman, President, CEO & Secretary
  • Maximo F. NouguesMaximo F. Nougues
    Chief Financial & Accounting Officer
  • Alvin F. Wong
    Chief Scientific Officer
  • Jeffrey Ludwig
    Chief Commercial Officer
  • Mariann Ohanesian
    Senior Director-Investor Relations













PBYI Stock - Frequently Asked Questions

Should I buy or sell Puma Biotechnology stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBYI shares.
View PBYI analyst ratings
or view top-rated stocks.

What is Puma Biotechnology's stock price forecast for 2023?

1 analysts have issued 12 month price objectives for Puma Biotechnology's shares. Their PBYI share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 67.0% from the stock's current price.
View analysts price targets for PBYI
or view top-rated stocks among Wall Street analysts.

How have PBYI shares performed in 2023?

Puma Biotechnology's stock was trading at $4.23 on January 1st, 2023. Since then, PBYI stock has increased by 13.2% and is now trading at $4.79.
View the best growth stocks for 2023 here
.

When is Puma Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our PBYI earnings forecast
.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.78. The biopharmaceutical company earned $46.20 million during the quarter, compared to analysts' expectations of $53.44 million. Puma Biotechnology had a net margin of 4.50% and a trailing twelve-month return on equity of 84.14%. The firm's quarterly revenue was down 9.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.79) earnings per share.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.84%), AlphaCentric Advisors LLC (0.11%), Bank of Montreal Can (0.07%), Patriot Financial Group Insurance Agency LLC (0.06%), Commonwealth Equity Services LLC (0.02%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Langley Steinert, Maximo F Nougues, Michael Patrick Miller, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends
.

How do I buy shares of Puma Biotechnology?

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $4.79.

How much money does Puma Biotechnology make?

Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $218.62 million and generates $253.20 million in revenue each year. The biopharmaceutical company earns $-29,130,000.00 in net income (profit) each year or $0.22 on an earnings per share basis.

How many employees does Puma Biotechnology have?

The company employs 196 workers across the globe.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for the company is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at ir@pumabiotechnology.com, or via fax at 424-248-6501.

This page (NASDAQ:PBYI) was last updated on 2/8/2023 by MarketBeat.com Staff